We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure [email protected]
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter engages with ‘legacy’ in two respects. It argues that Article 15 of the International Covenant on Economic, Social and Cultural Rights (ICESCR), the so-called right to science, has no legacy. It has achieved only marginal real-world impact and remains largely aspirational – all potential. By contrast, Graeme Laurie’s legacy, grounded in the public good and a strong sense of humanism, is significant and informative. Through multiple strands and projects, he has engaged deeply with the social contract between actors in the health setting, developing and refining the tools that could be used to help shape science and science governance in positive ways. Through an exploration of Article 15 ICESCR and select examples of Graeme’s scholarship, this chapter argues that the manifestation of Graeme’s legacy – the calling upon of his legacy – is what we need to generate some positive legacy for the sadly fallow ‘right to science’ articulated in Article 15 ICESCR. If we do this, it might one day have a legacy of its own.
The construction of governance frameworks for new health technologies is a complex process for most countries, particularly for developing countries. They must grapple with ‘old’ structures and ways of doing things while striving to plant the seeds of the ‘new’, which will put them on a higher level to promote science as well as access to new drugs and treatments. To achieve these goals, international collaboration is a key element. Argentina issued a regulation for advanced therapy medicinal products at the end of 2018. This chapter describes the objectives and actors involved in that process. It focuses on how internal tensions regarding whether to regulate were solved, considering the regulatory harmonisation process promoted by the European Medicines Agency and the US Food and Drug Administration, and the self-regulatory diversification promoted by China and other countries. Special mention is made of the importance of identifying social values and constructing a vision to guide the exercise of ‘foresight’ in law, which resulted in the design and implementation of the new regulation and governance of the system.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.